Frequency of fungal isolation and antifungal susceptibility pattern of the fungal isolates from nasal polyps of chronic rhinosinusitis patients at a tertiary care centre in north India.
Sinonasal polyposis is considered to be the end-result of a chronic inflammatory process in the sinonasal mucosa. Its underlying mechanisms are still unclear, but the involvement of fungi has been suggested for many years. In the present study, we retrospectively evaluated the clinical and mycological profile of 161 patients with chronic rhinosinusitis (CRS) and nasal polyps who were undergoing surgery at our tertiary care facility during 2002 to 2010. CT scan findings and per-operative presence of allergic mucin were provisionally suggestive of fungal rhinosinusitis (FRS) in all the patients. Total serum IgE and peripheral eosinophilia were noted. Histological examination of polyp tissue showed eosinophilic mucin in 100% of the cases and the incidence of allergic fungal rhinosinusitis (AFRS) was 83.9% in the patient population. KOH and/or culture were positive for fungal hyphae or yeast in 93% (150/161) of the patients. Aspergillus spp. were the most commonly recovered isolates (70%). MICs of all A. flavus and A. fumigatus isolates were within the susceptible zone for itraconazole, voriconazole, and amphoterecin B. In conclusion, allergic fungal rhinosinusitis (FRS) is a common disorder in patients with sinonasal polyposis and due to its recurrent and intractable nature, a high degree of clinical suspicion for the presence of FRS in nasal polyposis should be considered.
Department of Microbiology, University College of Medical Sciences and Guru Tegh Bahadur Hospital, Dilshad Garden, Delhi, India. drsarika6@gmail.com
Sarika
S
Jain
Shukla
S
Das
Neelima
N
Gupta
Junaid Nasim
JN
Malik
D000328:Adult; D000666:Amphotericin B / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology*; D001228:Aspergillosis / Q000453:epidemiology / Q000382:microbiology; D002908:Chronic Disease; D005260:Female; D005658:Fungi / Q000145:classification* / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D015994:Incidence; D007194:India / Q000453:epidemiology; D017964:Itraconazole / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009077:Mucins / Q000378:metabolism; D009181:Mycoses / Q000453:epidemiology / Q000382:microbiology*; D009298:Nasal Polyps / Q000453:epidemiology / Q000382:microbiology*; D011743:Pyrimidines / Q000494:pharmacology; D012189:Retrospective Studies; D012221:Rhinitis, Allergic, Perennial / Q000453:epidemiology / Q000382:microbiology*; D012852:Sinusitis / Q000453:epidemiology / Q000382:microbiology*; D063128:Tertiary Health Care; D014057:Tomography, X-Ray Computed; D014230:Triazoles / Q000494:pharmacology; D065819:Voriconazole
D000935:Antifungal Agents; D009077:Mucins; D011743:Pyrimidines; D014230:Triazoles; D017964:Itraconazole; D007073:Immunoglobulin E; D000666:Amphotericin B; D065819:Voriconazole